Knee Surgery, Sports Traumatology, Arthroscopy · 13 Nov 2026
Bone marrow stimulation improves 12‐month clinical outcomes after isolated meniscal repair: A double‐blind randomized controlled trial
Nithi Pakmaneeh-index 1, Chalermchai Limitlaohaphan, Nadhaporn Saengpetch, Chusak Kijkunasathian, Chatchawan Lertbutsayanukul, Thitiphol Wanitchanont, Sorawut Thamyongkit, Praman Fuangfa, Chaiyanun Vijittrakarnrungh-index 2
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Purpose To compare short‐term clinical outcomes and meniscal healing on magnetic resonance imaging (MRI) at 12 months between standard arthroscopic meniscal repair and repair augmented with bone marrow stimulation (BMS) in isolated meniscal tears. Methods In this prospective, two‐centre, double‐blind randomized controlled trial, patients aged 18–60 years with an isolated meniscal tear confirmed on MRI were randomized 1:1 to standard repair or repair augmented with BMS. Medial, lateral and bicompartmental tears were included. The primary outcome was the International Knee Documentation Committee (IKDC) subjective score at 12 months. Secondary outcomes were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lysholm score, Tegner activity scale, pain on a visual analogue scale (VAS), patient satisfaction, operative time, adverse events and meniscal healing on 12‐month MRI (3.0‐T) (Crues classification, two‐blinded assessors). Results Fifty patients (mean age 40.2 years; 21 male and 29 female) were randomized; all completed follow‐up. Baseline characteristics were balanced; the augmented group received significantly more sutures (4.2 ± 1.4 vs. 3.3 ± 1.1; p = 0.011) and had fewer horizontal tears (44% vs. 76%; p = 0.042). At 6 months, Lysholm and satisfaction scores already favoured the augmented group. At 12 months, it was superior for the IKDC score (82.5 ± 12.6 vs. 56.5 ± 18.5), WOMAC score (14.6 ± 20.0 vs. 41.8 ± 32.5), Lysholm score (91.8 ± 6.4 vs. 72.6 ± 17.2), Tegner activity scale (median 5.0, interquartile range [IQR] 4.0–6.0 vs. 3.0, IQR 2.0–4.0), pain (0.6 ± 0.7 vs. 2.3 ± 2.3) and satisfaction (9.7 ± 0.6 vs. 7.9 ± 1.7); all p < 0.05. MRI healing did not differ between groups ( p = 0.783; unhealed: 2/25 [8%] per group); operative time was similar, and no complications occurred within 12 months. Conclusions In this cohort, BMS augmentation was associated with superior patient‐reported outcomes at 12 months, without additional complications or an increase in operative time. Meniscal healing on MRI did not differ between groups. These positive short‐term findings helped to prove the benefit of BMS augmentation, although confirmation in larger trials with longer follow‐up and structural assessment is required to clarify the effectiveness, durability and indications of BMS. Level of Evidence Level I, therapeutic randomized controlled trial.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Chaiyanun Vijittrakarnrung has the highest h-index among the authors (2).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (41)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 21 more references
A free account opens the rest of the citing papers and references on every paper’s page.